



Xcess Biosciences Inc.

7144 N Harlem Ave #169
Chicago, IL 60631 USA

<http://www.xcessbio.com>


Toll free: 1-866-706-2330

Fax: 1-619- 810-0718

Email: info@xcessbio.com

Lysine Methyltransferase SETD8 Inhibitor – Ryuvidine

Chemical Name: 2-methyl-5-(p-tolylamino)benzo[d]thiazole-4,7-dione



Molecular Weight:	284.33
Formula:	C ₁₅ H ₁₂ N ₂ O ₂ S
Purity:	≥98%
CAS#:	265312-55-8
Solubility:	DMSO up to 20 mM
Storage	Powder: 4 °C 1 year DMSO: 4 °C 3 months -20 °C 1 year

Biological Activity:

Ryuvidine is a potent, selective and cell permeable lysine methyltransferase SETD8 inhibitor with IC₅₀ ~0.5 μM. It has cellular activity by suppressing the H4K20me1 mark of SETD8 and recapitulate characteristic S/G2/M-phase cell cycle defects as observed for RNAi-mediated SETD8 knockdown. It also inhibits cyclin-dependent kinase (CDK) 4 (IC₅₀ ~6.0 μM at CDK4/cyclin D1). SETD8's methyltransferase activity has been implicated in many essential cellular processes including DNA replication, DNA damage response, transcription modulation, and cell cycle regulation. Ryuvidine is a good tool compound to elucidate the diverse roles of SETD8.

How to Use:

In vitro: Ryuvidine was used at 10 μM final concentration in various in vitro assays.

In vivo: n/a

Reference:

1. Ryu CK, et al. 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. (2000) *Bioorg Med Chem Lett.* 10(5):461-4.
2. Blum G, et al. Small-molecule inhibitors of SETD8 with cellular activity. (2014) *ACS Chem Biol.* 9(11):2471-8.

Products are for research use only. Not for human use.